Combinaton or Individual Lipid-Lowering Therapy-What Is The Right Direction?
|Merkovska L, Jedlickova L, Jackova L, Fedacko J*, Jarcuska P, Janicko M, Novakova B and Pella D|
|Department of Internal Medicine and Centre of Excellence in Atherosclerosis Research, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Slovak Republic|
|Corresponding Author :||Jan Fedacko
Department of Internal Medicine
Louis Pasteur University Hospital Centre of Excellence in Atherosclerosis Research
Pavol Jozef Safarik University, Trieda SNP 1, 041 90 Kosice, Slovakia
Tel: + 421 911-315-924
Fax: + 421 55 799 6395
E-mail: [email protected]
|Received December 31, 2013; Accepted April 16, 2014; Published April 23, 2014|
|Citation: Merkovska L, Jedlickova L, Jackova L, Fedacko J, Jarcuska P, et al. (2014) Combinatonor Individual Lipid-Lowering Therapy-What Is The Right Direction? J Cardiovasc Dis Diagn 2:157. doi:10.4172/2329-9517.1000157|
|Copyright: © 2014 Merkovska L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Dyslipidemia is one of the most important risk factor for cardiovascular diseases, which are the main cause of death worldwide. There are two treatment options for dyslipidemia that complement each other. Despite the spread of lipid-lowering therapy and its increasing use in clinical practice, a large numbers of patients still remain in high “residual cardiovascular risk.” Currently at the forefront of lipid-lowering agents, statins significantly lower LDLcholesterol but in the terms of effect on the levels of triglycerides and HDL-cholesterol there is much less impact. This is a serious problem, especially in patients with atherogenic dyslipidemia, typical for patients with metabolic syndrome. For this reason, high attention has recently been given to combination of lipid-lowering agents. It is also important to mention the important pleiotropic effects of hypolipidemics. This article provides an overview of current lipid-lowering agents, their comparisons as well as new recommendations in the management of dyslipidemia.